Zinbryta vs. Aubagio

• Are Aubagio and Zinbryta the Same Thing?
• What Are Possible Side Effects of Zinbryta?
• What Are Possible Side Effects of Aubagio?
• What Is Zinbryta?
• What Is Aubagio?
• What Drugs Interact with Zinbryta?
• What Drugs Interact with Aubagio?
• How Should Zinbryta Be Taken?
• How Should Aubagio Be Taken?

Zinbryta (daclizumab) and Aubagio (teriflunomide) are used to treat patients with relapsing forms of multiple sclerosis (MS).

Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Zinbryta and Aubagio belong to different drug classes. Zinbryta is an interleukin-2 receptor blocking antibody and Aubagio is a pyrimidine synthesis inhibitor.

Side effects of Zinbryta and Aubagio that are similar include influenza.

Side effects of Zinbryta that are different from Aubagio include runny or stuffy nose, upper respiratory tract infection, bronchitis, skin rash (including drug rash), mouth pain, sore throat, eczema, swollen lymph nodes, depression, increased alanine aminotransferase (ALT), anemia, acne, and fever.

Side effects of Aubagio that are different from Zinbryta include liver problems, hair loss or thinning hair, nausea, diarrhea, burning or prickly feeling in your skin, and numbness or tingling in your hands or feet that is different from your MS symptoms.

Zinbryta may interact with drugs or herbal products that are toxic to the liver.

Aubagio may interact with "live" vaccines, cholestyramine, methotrexate, rifampin, warfarin, birth control pills or hormone replacement therapy, cancer medicines; medicines to treat autoimmune disorders such as rheumatoid arthritis, lupus, or psoriasis; medicines to prevent organ transplant rejection, cholesterol-lowering medications, and steroids.

Common side effects of Zinbryta include:

• runny or stuffy nose
• upper respiratory tract infection
• rash, including drug rash
• influenza
• skin rash
• mouth pain
• sore throat
• bronchitis
• eczema
• swollen lymph nodes
• depression
• increased alanine aminotransferase (ALT)
• acne
• anemia, and
• fever

Less common side effects of Zinbryta include:

• abnormal liver function test,
• decreased lymphocyte count
• diarrhea
• dry skin
• skin redness
• hair bumps (folliculitis)
• increased liver enzymes
• laryngitis
• enlarged lymph nodes
• pneumonia
• itching
• psoriasis
• skin peeling
• toxic skin eruption, and
• viral infection

Common side effects of Aubagio include:

• liver problems,
• influenza,
• hair loss or thinning hair,
• nausea,
• diarrhea,
• burning or prickly feeling in your skin, or
• numbness or tingling in your hands or feet that is different from your MS symptoms.

Tell your doctor if you have serious side effects of Aubagio including:

• fever,
• chills,
• body aches,
• flu symptoms,
• sores in your mouth and throat,
• itching,
• tired feeling,
• loss of appetite,
• dark urine,
• clay-colored stools,
• yellowing of the skin or eyes,
• fast or racing heartbeats,
• confusion,
• little or no urinating,
• chest pain,
• dry cough,
• wheezing,
• feeling short of breath,
• skin redness or peeling,
• swelling,
• rapid weight gain, or
• severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Zinbryta (daclizumab) injection is an interleukin-2 receptor blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Aubagio (teriflunomide) is a pyrimidine synthesis inhibitor used to treat relapsing forms of multiple sclerosis (MS).

Zinbryta may interact with hepatotoxic drugs or herbal products. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant before taking Zinbryta. It is unknown if it would affect a fetus. It is unknown if Zinbryta passes into breast milk or if it would affect a nursing infant. Consult your doctor before breastfeeding.

Aubagio may increase exposure of ethinyl estradiol and levonorgestrel. Patients taking Coumadin (warfarin) should be closely monitored as interactions may occur. Aubagio may cause major birth defects if used during pregnancy. Pregnancy must be excluded before starting treatment with Aubagio. Pregnancy must be avoided while taking Aubagio treat relapsing forms of multiple sclerosis (MS). If Aubagio is used during pregnancy, or if the patient becomes pregnant while taking Aubagio, the drug should be discontinued immediately and an accelerated elimination procedure should be initiated. Consult your doctor before breastfeeding.

The recommended dosage of Zinbryta is 150 milligrams once monthly.

The recommended dose for Aubagio is 7 mg or 14 mg taken orally, once daily, with or without food.